Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00471536 · OUTCOME

Confirmed Tumor Response (CR and PR)

Pazopanib in Treating Patients With Metastatic Urothelial Cancer · Source last updated 2014-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Documented on 2 consecutive evaluations 8 weeks apart from the start of the treatment until disease progression/recurrence, assessed up to 1 year

What was measured

Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)19

Reported measurements

Confirmed Partial Response (PR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)0Not reportedNot reportedNot reportedNot reported
Confirmed Complete Response (CR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Confirmed Partial Response (PR)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Confirmed Complete Response (CR)
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations.
groups
  1. description
    Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
param Type
NUMBER
reporting Status
POSTED
time Frame
Documented on 2 consecutive evaluations 8 weeks apart from the start of the treatment until disease progression/recurrence, assessed up to 1 year
title
Confirmed Tumor Response (CR and PR)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice